Navigation Links
Pharmos Corporation Reports 2007 Third Quarter Results
Date:10/30/2007

imately 480 female patients with diarrhea-predominant or alternating IBS at up to 55 participating U.S. centers over an 18-month period. Enrollment of patients in the study is currently on schedule.

Additional but relatively minimal research and development expenses were incurred during the quarter in connection with the Company's commencement in June 2007 of a Phase 2a clinical study of its topical NanoEmulsion drug delivery technology formulated with 3% diclofenac as a treatment for osteoarthritis. Up to eight centers in Israel will enroll a total of approximately 126 subjects over a nine-month period. Gross expenses for other research and development projects in early stages of development for the third quarter 2007 and 2006 were relatively unchanged at $0.9 million.

The decrease in general and administrative expenses is due primarily to lower professional fees and investor relations costs in connection with the Company's acquisition of Vela Pharmaceuticals, which was ongoing in the third quarter 2006 and completed by the fourth quarter 2006.

For the year-to-date period ended September 30, 2007, Pharmos recorded a net loss of $12.9 million, or $0.51 per share compared to a net loss of $11.3 million, or $0.60 per share in the same period in 2006. The increase in net loss is due to increased operating expenses and a decrease in net other income. Total operating expenses increased 7% to $13.7 million in the current year-to-date period from $12.8 million in the same period in 2006, primarily due to increased research and development expenses and lower grant receivables. Gross research and development expenses increased 41% to $9.3 million from $6.6 million, reflecting increased clinical trial-related activities. Grant receivables decreased to $0.8 million from $1.1 million in the same period in 2006. Higher research and development expenses were partially offset by a 29% decrease in general and administrative expenses to $5.0 million from $7.0 milli
'/>"/>

SOURCE Pharmos Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
11. Sonic Foundry reports GAAP loss as Q2 revenues rise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013 In Early 2013, ... of biotoxin related illnesses , announced his vision for ... to advance his protocol for treating Chronic Inflammatory Response ... third physician to achieve certification in the Shoemaker Protocol. ... to practice the Shoemaker Protocol in other parts of ...
(Date:5/17/2013)... 17, 2013 Dr. Sparano is Professor ... Health at the Albert Einstein College of Medicine and ... Montefiore Medical Center. He is also Associate Director ... leads the Einstein Breast Cancer Working Group, a multidisciplinary ... cancer research. He also serves as Vice Chair of ...
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in Photonics ... recent annual meeting drew praise from community leaders from ... called the action “a huge step forward … a ... innovation.” , The Board of Stakeholders voted to approve ... at its 29 April meeting in Brussels, which was ...
(Date:5/17/2013)... SAN JOSE, Calif. , May 17, 2013 ... an agreement has been reached with ... entire portfolio of anti-infective human monoclonal antibody (mAb) ... six anti-infective human mAb products for treatment of ... strains of Staphylococcus aureus , Pseudomonas ...
Breaking Biology Technology:Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... NEW YORK, Oct. 26 Signal Genetics, the parent ... testing company focused on oncology, today announced the formation ... Kenneth Anderson, M.D. Director, Jerome ... Kraft Family Professor of Medicine, Harvard Medical School ...
... BASKING RIDGE, N.J., Oct. 26 Regado Biosciences, a ... with active control agents, announced that David J. Mazzo, ... Oppenheimer 21st Annual Healthcare Conference.  Dr. Mazzo,s presentation will ... City on Tuesday, November 2, 2010 at 10:45 a.m. ...
... SAN DIEGO, Oct. 26 Optimer Pharmaceuticals, Inc. (Nasdaq: ... Oppenheimer,s 21st Annual Healthcare Conference at the Waldorf-Astoria Hotel ... at 10:15 a.m. Eastern Time. (Logo: ... Live audio webcast of this presentation will be ...
Cached Biology Technology:Signal Genetics Announces Establishment of Scientific Advisory Board 2Signal Genetics Announces Establishment of Scientific Advisory Board 3Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City 3Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference 2
(Date:5/20/2013)... URBANA - A National Science Foundation (NSF) planning grant ... Drying (CARD), a joint program of the University of ... Worcester, Mass. , "CARD will be devoted to research ... other agricultural products; forestry and paper products; chemical products; ... I professor of food science and human nutrition and ...
(Date:5/20/2013)... Boulder, Colo., USA New Geology ... 16 May 2013 cover a wide swath of ... tectonics, oceanography, geophysics, and paleobotany. Locations studied include ... mine at Alpi Apuane, Italy; Ukraine; Mars; and ... , 1. Rubies, jadeite, and plate tectonics;, ...
(Date:5/19/2013)... California, Davis have engineered a strain of photosynthetic cyanobacteria ... report their findings today at the 113th General Meeting ... work, we used synthetic biology approaches to probe and ... energy for growth) cyanobacterial metabolism for the ability to ... researcher on the study. He is part of ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11
... time have assessed dolphin and porpoise populations around the ... gear and recommended nine urgent priorities for action in ... nine projects highlight species threatened by bycatch that will ... to languish without intervention. , The list of dolphins ...
... in Alaska's tundra, and a corresponding northward progression of the ... of warmer and longer summers in the Alaskan Arctic according ... 22, 2005, issue of Science Express. , The resulting atmospheric ... what might be observed if there was a doubling of ...
... University of York are warning that dramatic changes may soon ... They believe the effect may be on a similar scale ... the African forest decline 2,500 years ago. , Scientists in ... climate fluctuations on the continent by modelling the responses of ...
Cached Biology News:Canada's first embryonic stem cell lines 2Canada's first embryonic stem cell lines 3Lands surface change on Alaska tundra creating longer, warmer summers in Arctic 2York scientists warn of dramatic impact of climate change on Africa 2
Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
Recombinant Mouse Wnt-3a...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Biology Products: